NEW YORK, Aug. 10, 2017 /PRNewswire/ --Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).
On November 6, 2015, Dr. Reddy's announced that it had received a warning letter issued by the U.S. Food and Drug Administration ("FDA") regarding quality control standards at three of Dr. Reddy's manufacturing plants in India. On this news, shares of Dr. Reddy's fell $11.75 per share or 18.01% to close at $53.50 on November 6, 2015.
Then, on August 10, 2017, Dr. Reddy's disclosed that the Regulatory of Germany did not renew the good manufacturing practices compliance certificate of a manufacturing unit of Dr. Reddy's German subsidiary, Betapharm Arzneimittel GmbH. On this news, Dr. Reddy's share price declined.
If you invested in Dr. Reddy's stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/RDY. There is no cost or obligation to you.
You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to email@example.com.
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
View original content with multimedia:http://www.prnewswire.com/news-releases/dr-reddys-investor-alert-faruqi--faruqi-llp-encourages-investors-who-suffered-losses-exceeding-100000-investing-in-dr-reddys-laboratories-limited-to-contact-the-firm-300503025.html
SOURCE Faruqi & Faruqi, LLP